About CLINUVEL

Contact

Head Office

CLINUVEL PHARMACEUTICALS LIMITED,
Level 6,
15 Queen Street,
Melbourne
Victoria 3000
Australia

Tel: +61 3 9660 4900
Fax: +61 3 9660 4909
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

UK office

Wesley House,
Bull Hill
Leatherhead, KT22 7AH
United Kingdom

Tel: +44 1372 860 765

Singapore office

9 Temasek Blvd #29-01
Singapore 038989

US Office

PO BOX 7388,
Menlo Park, CA 94026

Swiss Office

Zugerstrasse 76a,
6340 Baar,
Switzerland

Tel: +41 41 763 1782
Fax: +41 41 763 1784
 

 

 

CLINUVEL receives a large number of inquiries every day. For a list of frequently asked questions, please click here.

For more information on CLINUVEL’s program for SCENESSE® in EPP, please go to the following page.

For more information on CLINUVEL’s program for SCENESSE® in Vitiligo, please go to the following page.

If you have any additional questions, you can send us a message by filling out this online form.
If you have any investor related questions, you can send us a message by filling out this online form.
If you experience any side effects while using a CLINUVEL product, please feel free to contact us at This email address is being protected from spambots. You need JavaScript enabled to view it.

Latest Company Announcements

19 September 2017

CLINUVEL PROVIDES UPDATE ON SCENESSE® FDA FILING

CLINUVEL PHARMACEUTICALS LTD today announced an update on its submission of the New Drug Application (NDA) for CLINUVEL’s drug SCENESSE® (afamelanotide 16 mg) to the US Food and Drug Administration (FDA).

Read More
06 September 2017

Appendix 3B

Appendix 3B - New issue announcement

Read More
30 August 2017

Appendix 4E - Preliminary Final Report 2016/17

Appendix 4E - Preliminary Final Report 2016/17

Read More
08 August 2017

Form 604, 09 August 2017

Notice of change of interests of substantial holder

Read More
31 July 2017

Appendix 4C - Quarterly report

Appendix 4C

Read More
25 July 2017

CLINUVEL Newsletter - July 2017

For those who have followed the Company over the years, the journey of our teams has most often been counter-current to arrive at the present point.

Read More

Quick Links